|
Start Date:12/17/2020
Start Time:9:00 AM EST
Duration:180 minutes
Abstract:
Molecular Partners plans to share updates on its oncology programs and preliminary data from the Phase 1 study of MP0420, which is being developed for the treatment of COVID-19 under a collaboration with Novartis. In addition, Patrick Amstutz, Ph.D., Chief Executive Officer of Molecular Partners will describe the Company’s strategy for portfolio growth and expansion.
If you're already registered for the Molecular Partners Investor Day 2020 webcast, click below:
ALREADY REGISTERED?
Speakers
$-[WCSpeakerDisplayHTML]-$
|
Molecular Partners Investor Day 2020
Registration Is Closed
|
|
|
|